Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Tuesday 20 April, 2021

C4X Discovery

Board Appointment

RNS Number : 9566V
C4X Discovery Holdings PLC
20 April 2021
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Board Changes

 

C4X Discovery appoints Simon Harford as Non-Executive Director

 

GSK and Eli Lilly industry financial veteran further strengthens Board

 

 

20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect.

 

Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies.  Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017.  Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals.  During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee.  Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations.  He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly. 

 

Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based.  His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior.  We welcome Simon to the Board and look forward to working closely with him."

 

Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value."

 

In accordance with Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies, additional information for Simon Nicolas Reade Harford, aged 60, is set out below:

 

Current Directorships

Previous Directorships (last 5 years)

N/A

Liquent, Inc

PAREXEL International Corporation

 

As of the date of this announcement, Simon Harford holds no ordinary shares in the capital of the Company.

 

There is no further information to disclose in respect of these appointments under Rule 17 and Schedule 2 paragraph (g) of the AIM Rules.

 

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAILMPTMTIBBAB

a d v e r t i s e m e n t